Vivesto

Data from ADME studies (Absorption, Distribution, Metabolism, and Excretion) and secondary pharmacology studies confirm that Cantrixil has suitable physicochemical properties and an acceptable safety profile with minimal off-target effects, supporting continued development in bladder and blood cancer indications. Additional in vitro and in vivo studies are planned during 2024 to ensure the properties, safety and efficacy of the drug before proceeding to clinical trials.

“These supplementary studies provide essential information about Cantrixil and build upon earlier pharmacological and toxicological studies that are included in the preclinical evaluation required by the regulatory authorities. We are now looking forward to continuing the development of Cantrixil and preparing for clinical studies in these hard-to-treat cancer indications,” said Erik Kinnman, CEO of Vivesto.

The preclinical data package for Cantrixil is currently being extended as bladder and blood cancers are indications that require routes of drug administration not investigated previously. Both bladder and blood cancer have high unmet medical needs and significant commercial potential.

Vivesto has already obtained positive results with Cantrixil, which has shown strong cytotoxic effects at low doses in cell lines derived from patients with untreated and relapse/refractory hematological cancers including leukemia, non-Hodgkin lymphoma and multiple myeloma.

About Cantrixil
Cantrixil is a drug candidate being developed for the treatment of late-stage cancer and consists of the active molecule TRX-E-002-1, a potent third generation benzopyran, encapsulated in a cyclodextrin. Cantrixil targets a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) that are thought to be responsible for disease recurrence.

Vivesto acquired the global development and commercialization rights for Cantrixil in 2021.
To maximize the commercial potential of the Cantrixil program, Vivesto has in 2023 decided to focus the further development of the program on bladder cancer and blood cancer.

For more information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from hard-to-treat cancer. The company develops projects with the potential to offer new treatment options for cancer patients with high medical needs. Vivesto has the capacity and expertise to develop drugs from early preclinical development to clinical phase. Late clinical-phase and commercial development is intended to take place through partnerships with other pharmaceutical companies.

Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. In addition, Vivesto is developing the cancer programs Cantrixil and Docetaxel micellar, and the veterinary oncology program Paccal Vet (paclitaxel micellar) which is being developed for the treatment of malignant melanoma and hemangiosarcoma in dogs.

Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.